UK Expands Wegovy Approval to Include MASH Treatment
- nuaxia
- il y a 5 heures
- 3 min de lecture
The MHRA has conditionally approved Novo Nordisk’s GLP-1 therapy for adults with metabolic-associated steatohepatitis, marking another milestone in the evolution of obesity medicines.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has expanded the approved use of Novo Nordisk's Wegovy (semaglutide) to include the treatment of metabolic-associated steatohepatitis (MASH).
The conditional approval covers adults with MASH and moderate-to-advanced liver fibrosis, adding a third major indication for the GLP-1 therapy alongside obesity management and cardiovascular risk reduction.
The decision further strengthens Wegovy's position as one of the most versatile GLP-1 medicines currently on the market.
Conditional Approval for Patients with Liver Fibrosis
The MHRA has granted a conditional marketing authorisation, meaning Novo Nordisk must continue generating evidence from ongoing clinical studies before full approval is confirmed.
The regulator will review updated safety and efficacy data annually as additional evidence becomes available.
According to the MHRA, current clinical data indicate that semaglutide represents a safe and effective treatment option for eligible MASH patients.
Building on Positive Phase III Data
The approval follows encouraging results from the Phase III ESSENCE trial, which previously supported Wegovy's approval in the United States.
After 72 weeks of treatment:
37% of patients experienced improved liver fibrosis without worsening steatohepatitis, compared with 22.5% receiving placebo.
62.9% achieved resolution of steatohepatitis without additional liver scarring, versus 34.1% in the placebo group.
These findings positioned Wegovy as the first GLP-1 receptor agonist approved for MASH, expanding the therapeutic potential of a drug class originally developed for diabetes and obesity.
Expanding Global Momentum
The UK joins a growing list of markets approving semaglutide for MASH.
Wegovy received US approval for the indication last year and has also secured approval in Japan. Within the European Union, the therapy is authorised for MASH under the brand name Kayshild.
The expanding regulatory footprint reflects growing confidence in GLP-1 therapies beyond weight management and diabetes.
Competition in the MASH Market
Despite Wegovy's momentum, competition within the MASH landscape continues to intensify.
Madrigal Pharmaceuticals' Rezdiffra (resmetirom) remains the first therapy specifically developed for MASH and is expected to continue playing a significant role, particularly among patients without obesity who may not require the weight-loss benefits associated with GLP-1 medicines.
However, Wegovy enters the market with considerable advantages, including widespread physician familiarity, an established safety profile, and the commercial reach of Novo Nordisk.
As additional therapies progress through development, clinicians are likely to have an increasingly diverse range of treatment options tailored to different patient populations.
Why the Approval Matters
The expanded indication highlights several broader trends across healthcare:
GLP-1 medicines continue to expand beyond their original metabolic indications.
MASH is rapidly becoming one of the most active areas of pharmaceutical innovation.
Regulators are increasingly using conditional approvals to accelerate access while longer-term evidence is collected.
The future MASH treatment landscape is expected to include multiple therapeutic classes addressing different aspects of disease progression.
Summary
The MHRA has conditionally approved Novo Nordisk's Wegovy for adults with metabolic-associated steatohepatitis (MASH) and moderate-to-advanced liver fibrosis.
The decision marks another significant expansion for semaglutide, reinforcing the growing role of GLP-1 therapies beyond obesity and diabetes while intensifying competition in the emerging MASH treatment market.
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires